絞り込み

17360

広告

News from the melanoma sessions of the European Cancer Congress 2017.

著者 Rutkowski P , Kozak K
BMC Med.2017 03 17 ; 15(1):57.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (8view , 0users)

Full Text Sources

Medical

Other Literature Sources

Research Materials

During the European Cancer Congress, the melanoma sessions focused on practice changing trials. Recent developments and approvals in immunotherapy and targeted agents have significantly changed the landscape of melanoma therapy in the metastatic setting and provide great promise for adjuvant and neoadjuvant treatment in high-risk locoregional disease. Perioperative (combined pre- and postoperative) strategies may be extremely beneficial for patients with bulky stage IIIC disease. The long-term results of the European Organisation for Research and Treatment of Cancer (EORTC) 18071 adjuvant trial ipilimumab versus placebo after complete resection of high-risk stage III melanoma, demonstrating improvement in overall survival, has established the reference bar for further trials with postoperative therapy.
PMID: 28302128 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード